Simon J. Clark

Co-founder @Complement Therapeutics

Tübingen, DE
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Jul 2021 — Present

Co-founder @Complement Therapeutics

View department →

London, GB

Clinical-stage BioTech founded to turn powerful new insights into innovative treatments for complement-mediated diseases

EDUCATION

2003 — 2006

University of Oxford

D.Phil, Biochemistry

1997 — 2002

University of Aberdeen

BSc (Hons), Biochemistry (with Immunology)

ABOUT SIMON J. CLARK

I lead a research team studying the molecular mechanisms driving age-related macular degeneration (AMD), the third leading cause of blindness worldwide. In particular I focus on the role of the complement system, a powerful part of a host’s immune system, in the development of this devastating disease and how the modulation of such as response can be harnessed to slow disease progression.My translational portfolio includes the development of novel complement modifiers that can be used as therapeutics in complement-mediated diseases of the eye, as well as around the body. I also help develop new diagnostic tools for complement driven disease and methods for patient stratification for future treatment. In 2021 I co-founded a biotech spin-out company, Complement Therapeutics, to take these new innovations forward into the clinic.In 2015 I co-founded the Manchester Eye Tissue Repository (ETR) with Prof. Paul Bishop, where genotyped and phenotyped human eye tissue is collected and stored to act as an international resource for academic research into eye diseases: one of the largest such resources in Europe.

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.